EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Plasma proteomic signatures improve risk stratification and personalized screening for gastric cancer

Xue Li, Wen-Hao Shi, Juan Zhu, Ying Chen, Bin Liu, Nai-Ren Zheng, Le Wang, Li Yuan, Ying-Ying Mao, Xiang-Dong Cheng, Ling-Bin Du iD

Gastric Cancer · 2026

DOI: 10.1007/s10120-026-01749-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastric Cancer, 2026. Verfasst von Xue Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zheji…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Proteomics, Biomarkers, Tumor, Early Detection of Cancer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Healthy Zhejiang One Million People Cohort, Zhejiang Key Laboratory of Prevention, Diagnosis and Therapy for Gastrointestinal Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Accurate identification of individuals at high risk of gastric cancer (GC) remains a major challenge for effective screening. We aimed to identify plasma proteomic signatures and develop a risk prediction model for GC risk stratification.

Methods

Plasma proteomic profiling was performed using liquid chromatography–tandem mass spectrometry in a case–control discovery set (100 GC cases and 94 controls). Candidate proteins were evaluated in 52,552 UK Biobank participants with a median follow-up of 13.63 years, during which 92 incident GC cases were identified. Risk models integrating clinical, genetic, and proteomic factors were developed using LASSO-penalized Cox regression with stability selection and internally validated using bootstrap resampling.

Results

Among 2306 differentially expressed proteins in discovery, 25 were replicated in validation at nominal significance ( P < 0.05) with consistent directions. Two proteins (CTSD and GGH) remained significant after false discovery rate correction. A primary proteomic model (clinical factors plus five proteins) improved discrimination versus clinical model (optimism-corrected C-index: 0.745 vs. 0.732, P = 0.046). Risk stratification revealed a clear GC risk gradient: hazard ratios were 6.08 (95% CI 2.15–17.20) for moderate-risk and 23.88 (95% CI 8.66–65.87) for high-risk groups. The risk score was also associated with GC risk as continuous variable (HR per standard deviation: 1.09, 95% CI 1.08–1.11). The 15-year cumulative incidence ranged from 0.02 to 0.56% across risk groups. Decision curve analysis indicated improved clinical utility.

Conclusions

Plasma proteomic signatures may improve GC risk stratification beyond traditional clinical factors and could support more targeted screening strategies. Further validation is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsProteomicsBiomarkers, TumorEarly Detection of CancerHumansFemaleMaleMiddle AgedCase-Control StudiesAgedRisk AssessmentPrecision MedicineFollow-Up StudiesRisk Factors

Stichwörter der Autor:innen

BiomarkerCancer preventionCancer screeningGastric cancerProteomics

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
  • Zhejiang Key Laboratory of Prevention, Diagnosis and Therapy for Gastrointestinal Cancer, Hangzhou, 310022, Zhejiang, China.
  • Analysis Center, Chemistry Department, Tsinghua University, Beijing, 100084, China.
  • Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, 211166, Jiangsu, China.
  • Department of Epidemiology, School of Public Health, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
  • Beijing Pineal Diagnostics Company Limited, Beijing, 102206, China.

ORCID-Profile: Ling-Bin Du

Förderung

  • National Natural Science Foundation of China
  • Healthy Zhejiang One Million People Cohort
  • Zhejiang Key Laboratory of Prevention, Diagnosis and Therapy for Gastrointestinal Cancer

Zitieren

APA

Li, X., Shi, W. H., Zhu, J., Chen, Y., Liu, B., Zheng, N. R., Wang, L., Yuan, L., Mao, Y. Y., Cheng, X. D., & Du, L. B. (2026). Plasma proteomic signatures improve risk stratification and personalized screening for gastric cancer. Gastric Cancer. https://doi.org/10.1007/s10120-026-01749-4

Vancouver

Li X, Shi WH, Zhu J, Chen Y, Liu B, Zheng NR, et al. Plasma proteomic signatures improve risk stratification and personalized screening for gastric cancer. Gastric Cancer. 2026. doi:10.1007/s10120-026-01749-4

BibTeX
@article{Li2026,
  author = {Li, Xue and Shi, Wen-Hao and Zhu, Juan and Chen, Ying and Liu, Bin and Zheng, Nai-Ren and Wang, Le and Yuan, Li and Mao, Ying-Ying and Cheng, Xiang-Dong and Du, Ling-Bin},
  title = {Plasma proteomic signatures improve risk stratification and personalized screening for gastric cancer},
  journal = {Gastric Cancer},
  year = {2026},
  doi = {10.1007/s10120-026-01749-4}
}
Kostenlos starten →